ArticleSignal transduction and targeted therapy2024

First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.

Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.